RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $14 from $11 and keeps an Outperform rating on the shares after its Q4 earnings beat. The company saw a strong finish to 2024 and gave solid initial guidance, the analyst tells investors in a research note. Early signs that the strategic overhaul to the Diabetes business announced last quarter may be taking hold, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue